This study, called ELEPHAS-05, is looking for people with suspected or confirmed cancer, including advanced solid tumors, bladder cancer, and triple-negative breast cancer (TNBC). It aims to understand how well immunotherapy might work for you by studying your tumor tissue. Researchers will collect tumor samples during a biopsy (a procedure to remove tissue for examination) that you would already be having as part of your regular medical care. They will then compare how these tumor samples respond to immunotherapy in the lab with how patients actually respond to immunotherapy in real life. This will help them learn more about how immunotherapy works and predict its effectiveness. You must be at least 18 years old and new to treatment at the time of your biopsy to join.

Study design

This is an observational study with a planned enrollment of 2000 participants. It is not specified if this is a randomized or blinded study.

What's involved

You would undergo additional biopsy passes during a standard biopsy procedure. Tumor samples and clinical information will be collected.

Compensation

Not stated in the trial record.

Follow-up

The study duration is approximately 36 months from your enrollment to the end of the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.